lineage	VOC/VOI/Recombinant	gene_ORF_name	in_PANGO	nucleotide_position	del	ins	aa_name	mutation_type	mutation_effects	fixed_mutation	notes	curator_name	curator_orcid_id	Comment	mutation effect_source
B.1.1.7	VOC	S	y	23063	A	T	N501Y	nonsynonymous	increased affinity for hACE2, "associated with fast growing lineages", within the six key residues in the receptor binding domain (RBD), estimated to cause an increase of between 40% and 70% in transmissibility, Experimentally, ACE2 binding affinity increased 0.24 fold, Calculated disassociation constant for this variant is nearly four fold lower than wild type (455 pM vs 1600pM)		alt_voc_name=(20I/501Y.V1;501Y.V1;UK variant;VOC 202012/01)	Madeline	https://orcid.org/0000-0002-0548-891X		
B.1.1.7	VOC	S	y	23271	C	A	A570D	nonsynonymous	[not in pokay]		alt_voc_name=(20I/501Y.V1;501Y.V1;UK variant;VOC 202012/01)	Anoosha	https://orcid.org/0000-0001-5275-8866		
B.1.1.7	VOC	S	y	23604	C	A	P681H	nonsynonymous	May help infected cells create new spike proteins more efficiently  Recurrent deletions in vairous lineages related to several RBD mutations.  one of 4 residues comprising the insertion that creates a furin cleavage site between S1 and S2 in spike. The S1/S2 furin cleavage site of SARS-CoV-2 is not found in closely related coronaviruses and has been shown to promote entry into respiratory epithelial cells and transmission in animal models.  Pokay: "adjacent to the Spike protein furin cleavage site (cleavage of S into S1 and S2 subunits is required for viral membrane fusion and subsequent entry into host cells), a site shown to be highly immunogenic"		alt_voc_name=(20I/501Y.V1;501Y.V1;UK variant;VOC 202012/01)	Anoosha			https://www.nytimes.com/interactive/2021/health/coronavirus-variant-tracker.html#B117
B.1.1.7	VOC	S	y	23709	C	T	T716I	nonsynonymous	"Not in a major wildtype epitope, mutant increases PIWAS epitope score from 0.69% to 2.3% # Found in B.1.1.7 lineage, but assumed to not pay a major role in antigenicity." (Pokay)		alt_voc_name=(20I/501Y.V1;501Y.V1;UK variant;VOC 202012/01)	Anoosha			
B.1.1.7	VOC	S	y	24506	T	G	S982A	nonsynonymous	"Not in a major wildtype epitope, mutant has no significant effect on PIWAS epitope score # Found in B.1.1.7 lineage, but assumed to not pay a major role in antigenicity." (Pokay)		alt_voc_name=(20I/501Y.V1;501Y.V1;UK variant;VOC 202012/01)	Anoosha			
B.1.1.7	VOC	S	y	24914	G	C	D1118H	nonsynonymous	"Not in a major wildtype epitope, mutant has no significant effect on PIWAS epitope score # Found in B.1.1.7 lineage, but assumed to not pay a major role in antigenicity." (pokay)		alt_voc_name=(20I/501Y.V1;501Y.V1;UK variant;VOC 202012/01)	Anoosha/Madeline			
B.1.1.7	VOC	S	y	21765-21770 	6 deletions? what would be the best way to curate or map it?		HV 69-70 deletion	deletion	evasion to the human immune response but has also occurred a number of times in association with other receptor-binding domain (RBD) changes.  Has been detected in immunocompromised patients.  Enhances viral infectivity. "Fatal COVID-19 complications in immunocomprimised patient after immune escape from convalescent plasma" (Pokay) "# The delH69/V70 enhances viral infectivity, indicating its effect on virus fitness is independent to the N501Y RBM change [with which it is found in lineage B.1.1.7] # Possibly arisen as a result of the virus evolving from immune selection pressure in infected individuals and possibly only one chronic infection in the case of lineage B.1.1.7." (Pokay)		alt_voc_name=(20I/501Y.V1;501Y.V1;UK variant;VOC 202012/01)	Anoosha/Madeline			
B.1.1.7	VOC	S	y	21991-21993	3 deletions		Y144 deletion	deletion	# Alter the shape of the spike and may help it evade some antibodies. # Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 1% to 0.17% (poorer immune recognition) # Together with other B1.1.7 lineage mutational changes (Spike: N501Y, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 of 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.  # Haynes et al. (2021) https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1 # Massive reduction in S2M28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite "i"  # Massive reduction in S2X28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite "i"  # Massive reduction in S2X333 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite "i"  # Massive reduction in 4A8 monoclonal antibody EC50 (i.e. ablated recognition)  "# McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475"  (Pokay)		alt_voc_name=(20I/501Y.V1;501Y.V1;UK variant;VOC 202012/01)	Anoosha/Madeline			https://www.nytimes.com/interactive/2021/health/coronavirus-variant-tracker.html#B117
B.1.1.7	VOC	Orf8	y	28048	G	T	R52I	nonsynonymous	ORF8: There is a small amount of data about variants affecting ORF8, a viral accessory protein which may be involved in immune evasion by downregulation of MHC class I. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/959438/Technical_Briefing_VOC_SH_NJL2_SH2.pdf		alt_voc_name=(20I/501Y.V1;501Y.V1;UK variant;VOC 202012/01)	Anoosha			
B.1.1.7	VOC	Orf8	y	27972	C	T	Q27stop	nonsynonymous	truncates the ORF8 protein or renders it inactive and thus allows further downstream mutations to accrue.		alt_voc_name=(20I/501Y.V1;501Y.V1;UK variant;VOC 202012/01)	Anoosha			
B.1.1.7	VOC	Orf8	y	28111	A	G	Y73C	nonsynonymous	#Crystal structure of ORF8 shows two dimerization interfaces unique to SARS-CoV-2 genealogy. The R52I and Y73C mutations are localized at these interaction interfaces. In wild type strain, R52 forms H-bond contact with I121 from another protomer. Y73 forms part of crucial 73YIDI76 non-covalent ORF8 dimer interaction interface, unique to SARS-CoV-2. Presence of these interfaces enables ORF8 to form large scale assemblies, possibly aiding SARS-CoV-2 to evade and modulate host immune responses 		alt_voc_name=(20I/501Y.V1;501Y.V1;UK variant;VOC 202012/01)	Anoosha			https://www.biorxiv.org/content/10.1101/2021.01.01.425028v1.full
B.1.1.7	VOC	N	y	28280 GAT->CTA	GAT	CTA	D3L	nonsynonymous			alt_voc_name=(20I/501Y.V1;501Y.V1;UK variant;VOC 202012/01)	Anoosha			
B.1.1.7	VOC	N	y	28977	C	T	S235F	nonsynonymous	#predicted stabilization effect conferred by S235F to N protein		alt_voc_name=(20I/501Y.V1;501Y.V1;UK variant;VOC 202012/01)	Anoosha			https://www.biorxiv.org/content/10.1101/2021.01.01.425028v1.full
B.1.1.7	VOC	ORF1ab	y	3267	C	T	T1001I	nonsynonymous			alt_voc_name=(20I/501Y.V1;501Y.V1;UK variant;VOC 202012/01)	Anoosha			
B.1.1.7	VOC	ORF1ab	y	5388	C	A	A1708D	nonsynonymous			alt_voc_name=(20I/501Y.V1;501Y.V1;UK variant;VOC 202012/01)	Anoosha			
B.1.1.7	VOC	ORF1ab	y	6954	T	C	I2230T	nonsynonymous			alt_voc_name=(20I/501Y.V1;501Y.V1;UK variant;VOC 202012/01)	Anoosha			
B.1.1.7	VOC	ORF1ab	y	11288-11296	9 deletions		SGF 3675-3677 deletion	deletion			alt_voc_name=(20I/501Y.V1;501Y.V1;UK variant;VOC 202012/01)	Anoosha		 There are also 6 synonymous mutations with 5 in ORF1ab (C913T, C5986T, C14676T, C15279T, T16176C), and one in the M gene (T26801C).	
B.1.1.7	VOC	ORF1ab	n	913	C	T		synonymous			alt_voc_name=(20I/501Y.V1;501Y.V1;UK variant;VOC 202012/01)				
B.1.1.7	VOC	ORF1ab	n	5986	C	T		synonymous			alt_voc_name=(20I/501Y.V1;501Y.V1;UK variant;VOC 202012/01)	Anoosha			
B.1.1.7	VOC	ORF1ab	n	14676	C	T		synonymous			alt_voc_name=(20I/501Y.V1;501Y.V1;UK variant;VOC 202012/01)	Anoosha			
B.1.1.7	VOC	ORF1ab	n	15279	C	T		synonymous			alt_voc_name=(20I/501Y.V1;501Y.V1;UK variant;VOC 202012/01)	Anoosha			
B.1.1.7	VOC	ORF1ab	n	16176	T	C		synonymous			alt_voc_name=(20I/501Y.V1;501Y.V1;UK variant;VOC 202012/01)	Anoosha			
B.1.1.7	VOC	M	n	26801	T	C		synonymous			alt_voc_name=(20I/501Y.V1;501Y.V1;UK variant;VOC 202012/01)				
B.1.351	VOC	ORF1ab	n	1059	C	T	T265I	nonsynonymous		fixed	alt_voc_name=(501Y.V2;20H/501Y.V2;South African variant)	Madeline			
B.1.351	VOC	ORF1ab	y	5230	G	T	K1655N	nonsynonymous		fixed	alt_voc_name=(501Y.V2;20H/501Y.V2;South African variant)	Madeline			
B.1.351	VOC	ORF1ab	n	8660	C	T	H2799Y	nonsynonymous		not fixed	alt_voc_name=(501Y.V2;20H/501Y.V2;South African variant)	Madeline			
B.1.351	VOC	ORF1ab	n	8964	C	T	S2900L	nonsynonymous		not fixed	alt_voc_name=(501Y.V2;20H/501Y.V2;South African variant)	Madeline			
B.1.351	VOC	ORF1ab	n	10323	A	G	K3353R	nonsynonymous		fixed	alt_voc_name=(501Y.V2;20H/501Y.V2;South African variant)	Madeline			
B.1.351	VOC	ORF1ab	n	13843	G	T	D4527Y	nonsynonymous		not fixed	alt_voc_name=(501Y.V2;20H/501Y.V2;South African variant)	Madeline			
B.1.351	VOC	ORF1ab	n	17999	C	T	T5912I	nonsynonymous		not fixed	alt_voc_name=(501Y.V2;20H/501Y.V2;South African variant)	Madeline			
B.1.351	VOC	S	n	21614	C	T	L18F	nonsynonymous	"# Massive reduction in S2L28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite "i", but no effect on other mAbs within that supersite # McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475" (Pokay) contributor to convalescent plasma escape (Pokay)  # Likely play a role in protein folding and immune evasion and may have implications in viral virulence and vaccine design.	not fixed	alt_voc_name=(501Y.V2;20H/501Y.V2;South African variant)	Madeline/Anoosha			https://www.medrxiv.org/content/10.1101/2021.01.29.21250757v1.full-text
B.1.351	VOC	S	y	21801	A	C	D80A	nonsynonymous	contributor to convalescent plasma escape (Pokay)	fixed	alt_voc_name=(501Y.V2;20H/501Y.V2;South African variant)	Madeline			
B.1.351	VOC	S	y	22206	A	G	D215G	nonsynonymous	contributor to convalescent plasma escape (Pokay)	not fixed	alt_voc_name=(501Y.V2;20H/501Y.V2;South African variant)	Madeline			
B.1.351	VOC	S	n	22287	T	A	L242H	nonsynonymous	# Ablates binding of Spike N terminal domain targeting monoconal anibody 4A8, by disruption of N5-loop/supersite loop, may work synergistically with  # 501Y.V2 ("South African") lineage background variant R246I to disrupt paratope binding. # Wibmer et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1 (Pokay)	not fixed	unresolved region; alt_voc_name=(501Y.V2;20H/501Y.V2;South African variant)	Madeline			
B.1.351	VOC	S	n	22286-22294			L242_244L deletion; L242del,A243del,L244del	deletion	contributor to convalescent plasma escape (Pokay)  # Ablates binding of Spike N terminal domain targeting monoconal anibody 4A8, by disruption of N5-loop/supersite loop, may work synergistically with  # 501Y.V2 ("South African") lineage background variant R246I to disrupt paratope binding. # Wibmer et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1 (Pokay)	not fixed	unresolved region; alt_voc_name=(501Y.V2;20H/501Y.V2;South African variant)	Madeline			
B.1.351	VOC	S	n	22299	G	T	R246I	nonsynonymous	# Ablates binding of Spike N terminal domain targeting monoconal anibody 4A8, this residue is known to be key for CDR-H1 mediated # interactions. May work synergistically with 501Y.V2 ("South African") lineage background deletion 242del,243del,244del to disrupt paratope binding # via steric clash with residue R102. # Wibmer et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1  (Pokay)	not fixed	alt_voc_name=(501Y.V2;20H/501Y.V2;South African variant)	Madeline			
B.1.351	VOC	S	y	22813	G	T	K417N	nonsynonymous	# Helps the virus bind more tightly to human cells.  at a key residue in the RBD; contributor to convalescent plasma escape (Pokay); "#Experimentally, Spike gene expression increased 0.1 fold #Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012" (Pokay)  The spike RBD is the main target of neutralizing antibodies (NAbs) elicited during SARS- CoV-2 infection37. Class 1 antibodies have a VH3-53 restricted mode of recognition centred around spike residue K417. The K417N mutation abolish key interactions with class 1 NAbs, and likely contributes toward immune evasion at this site.	fixed	alt_voc_name=(501Y.V2;20H/501Y.V2;South African variant)	Madeline/Anoosha			https://www.krisp.org.za/manuscripts/MEDRXIV-2020-248640v1-de_Oliveira.pdf  https://www.nytimes.com/interactive/2021/health/coronavirus-variant-tracker.html#B117 
B.1.351	VOC	S	y	23012	G	A	E484K	nonsynonymous	can "escape several mAbs (including C121, C144, REGN10933, REGN10934) and some convalescent sera", at a key residue in the RBD; "substantially increases the amount of serum antibody needed to prevent infection of cells"; contributor to convalescent plasma escape; "# Ablates binding by class 2 mAbs such as C144 that do not directly interfere with ACE2 binding,  # BUT clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  # show pronounced increase in binding to the variant.  # Gaebler et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2"  (Pokay) #The mutation is in the spike protein and appears to have an impact on the bodyâ€™s immune response and, possibly, vaccine efficacy.	fixed	alt_voc_name=(501Y.V2;20H/501Y.V2;South African variant)	Madeline/Anoosha			https://www.bmj.com/content/bmj/372/bmj.n359.full.pdf
B.1.351	VOC	S	y	23063	A	T	N501Y	nonsynonymous	increased affinity for hACE2, "associated with fast growing lineages", within the six key residues in the receptor binding domain (RBD), estimated to cause an increase of between 40% and 70% in transmissibility, Experimentally, ACE2 binding affinity increased 0.24 fold, Calculated disassociation constant for this variant is nearly four fold lower than wild type (455 pM vs 1600pM); contributor to convalescent plasma escape (Pokay) "#Among the first selected variants in an in vitro evolution experiment for ACE2 binding. #Zahradnik et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.06.425392 #Experimentally, ACE2 binding affinity increased 0.06 fold #Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012", "# This mutation occurred in 100% of sequenced virions after 12 passages and led to a 4-fold decrease in convalescent plasma neutralization activity # Andreano et al. (2020)https://www.biorxiv.org/content/10.1101/2020.12.28.424451", "# Escape variant 100% appearance in 2 passages against Regeneron monoclonal antibody REGN10989 @ 50ug/mL (99% after one passage) # Baum et al. (2020) http://dx.doi.org/10.1126/science.abd0831 # Strong positive selection (up to 50% of supernatant sequences) after C121 monoclonal antibody assay, decreasing in subsequent passages # Strong positive selection (up to 44% of supernatant sequences) after after one round of C144 monoclonal antibody passage, then waning on subsequent passages # Weisblum et al. (2020) https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf # The engineered mutation cause 10-fold or more increase in the disassociation constant with many monoclonal antibodies (C144/C002/C121/C104/C110). # Barnes et al. (2020) https://www.nature.com/articles/s41586-020-2852-1_reference.pdf?origin=ppub # Mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody # Effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody # Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007", "# Ablates binding by class 2 mAbs such as C144 that do not directly interfere with ACE2 binding,  # BUT clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  # show pronounced increase in binding to the variant.  # Gaebler et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2" (Pokay)	fixed	alt_voc_name=(501Y.V2;20H/501Y.V2;South African variant)	Madeline			
B.1.351	VOC	S	y	23664	C	T	A701V	nonsynonymous		fixed	alt_voc_name=(501Y.V2;20H/501Y.V2;South African variant)	Madeline			
B.1.351	VOC	ORF3a	n	25563	G	T	Q57H	nonsynonymous		fixed	alt_voc_name=(501Y.V2;20H/501Y.V2;South African variant)	Madeline			
B.1.351	VOC	ORF3a	n	25904	C	T	S171L	nonsynonymous		fixed	alt_voc_name=(501Y.V2;20H/501Y.V2;South African variant)	Madeline			
B.1.351	VOC	E	y	26456	C	T	P71L	nonsynonymous		fixed	alt_voc_name=(501Y.V2;20H/501Y.V2;South African variant)	Madeline			
B.1.351	VOC	N	y	28887	C	T	T205I	nonsynonymous		fixed	alt_voc_name=(501Y.V2;20H/501Y.V2;South African variant)	Madeline			
P.1	VOC	ORF1ab	n	733	T	C		synonymous			alt_voc_name=(20J/501Y.V3;501Y.V3;Brazil variant;Manaus variant;B.1.1.28.1)	Madeline			
P.1	VOC	ORF1ab	n	2749	C	T		synonymous			alt_voc_name=(20J/501Y.V3;501Y.V3;Brazil variant;Manaus variant;B.1.1.28.1)	Madeline			
P.1	VOC	ORF1ab	y	3828	C	T	S1188L	nonsynonymous			alt_voc_name=(20J/501Y.V3;501Y.V3;Brazil variant;Manaus variant;B.1.1.28.1)	Madeline			
P.1	VOC	ORF1ab	y	5648	A	C	K1795Q	nonsynonymous			alt_voc_name=(20J/501Y.V3;501Y.V3;Brazil variant;Manaus variant;B.1.1.28.1)	Madeline			
P.1	VOC	ORF1ab	y	11288-11296			3675-3677 SGF	deletion			alt_voc_name=(20J/501Y.V3;501Y.V3;Brazil variant;Manaus variant;B.1.1.28.1)	Madeline			
P.1	VOC	ORF1ab	n	12778	C	T		synonymous			alt_voc_name=(20J/501Y.V3;501Y.V3;Brazil variant;Manaus variant;B.1.1.28.1)	Madeline			
P.1	VOC	ORF1ab	n	13860	C	T	T4532I	synonymous			alt_voc_name=(20J/501Y.V3;501Y.V3;Brazil variant;Manaus variant;B.1.1.28.1)	Madeline			
P.1	VOC	ORF1ab	n	17259			E5665D (VIROLOGICAL)	nonsynonymous			alt_voc_name=(20J/501Y.V3;501Y.V3;Brazil variant;Manaus variant;B.1.1.28.1)	Madeline			
P.1	VOC	ORF1ab	n	17259	G	T	S56651 (BIORXIV)	nonsynonymous			alt_voc_name=(20J/501Y.V3;501Y.V3;Brazil variant;Manaus variant;B.1.1.28.1)	Madeline			
P.1	VOC	S	y	21614	C	T	L18F	nonsynonymous			alt_voc_name=(20J/501Y.V3;501Y.V3;Brazil variant;Manaus variant;B.1.1.28.1)	Madeline			
P.1	VOC	S	y	21621	C	A	T20N	nonsynonymous			alt_voc_name=(20J/501Y.V3;501Y.V3;Brazil variant;Manaus variant;B.1.1.28.1)	Madeline			
P.1	VOC	S	y	21638	C	T	P26S	nonsynonymous			alt_voc_name=(20J/501Y.V3;501Y.V3;Brazil variant;Manaus variant;B.1.1.28.1)	Madeline			
P.1	VOC	S	y	21974	G	T	D138Y	nonsynonymous			alt_voc_name=(20J/501Y.V3;501Y.V3;Brazil variant;Manaus variant;B.1.1.28.1)	Madeline			
P.1	VOC	S	y	22132	G	T	R190S	nonsynonymous			alt_voc_name=(20J/501Y.V3;501Y.V3;Brazil variant;Manaus variant;B.1.1.28.1)	Madeline			
P.1	VOC	S	y	22812	A	C	K417T	nonsynonymous	Same site as the K417N mutation in the B.1.351 lineage. It may help the virus latch on tighter.		alt_voc_name=(20J/501Y.V3;501Y.V3;Brazil variant;Manaus variant;B.1.1.28.1)	Madeline/Anoosha			https://www.nytimes.com/interactive/2021/health/coronavirus-variant-tracker.html#B117
P.1	VOC	S	y	23012	G	A	E484K	nonsynonymous	can "escape several mAbs (including C121, C144, REGN10933, REGN10934) and some convalescent sera", at a key residue in the RBD; "substantially increases the amount of serum antibody needed to prevent infection of cells"  # Mutation occurs near the top of the coronavirus spike, where it alters the shape of the protein. This change may help the spikes evade some types of coronavirus antibodies.		alt_voc_name=(20J/501Y.V3;501Y.V3;Brazil variant;Manaus variant;B.1.1.28.1)	Madeline/Anoosha			https://www.nytimes.com/interactive/2021/health/coronavirus-variant-tracker.html#B118 
P.1	VOC	S	y	23063	A	T	N501Y	nonsynonymous	increased affinity for hACE2, "associated with fast growing lineages", within the six key residues in the receptor binding domain (RBD), estimated to cause an increase of between 40% and 70% in transmissibility, Experimentally, ACE2 binding affinity increased 0.24 fold, Calculated disassociation constant for this variant is nearly four fold lower than wild type (455 pM vs 1600pM)		alt_voc_name=(20J/501Y.V3;501Y.V3;Brazil variant;Manaus variant;B.1.1.28.1)	Madeline			
P.1	VOC	S	y	23525	C	T	H655Y	nonsynonymous	# Associated with reduced susceptibility to neutralizing antibodies 		alt_voc_name=(20J/501Y.V3;501Y.V3;Brazil variant;Manaus variant;B.1.1.28.1)	Madeline/Anoosha			https://www.medrxiv.org/content/10.1101/2021.01.28.21250666v1.full-text
P.1	VOC	S	y	24642	C	T	T1027I	nonsynonymous			alt_voc_name=(20J/501Y.V3;501Y.V3;Brazil variant;Manaus variant;B.1.1.28.1)	Madeline			
P.1	VOC	ORF3a	n	26149	T	C	S253P	nonsynonymous			alt_voc_name=(20J/501Y.V3;501Y.V3;Brazil variant;Manaus variant;B.1.1.28.1)	Madeline			
P.1	VOC	ORF8	y	28167	G	A	E92K	nonsynonymous			alt_voc_name=(20J/501Y.V3;501Y.V3;Brazil variant;Manaus variant;B.1.1.28.1)	Madeline			
P.1	VOC	ORF8	n	28269-28273		insG28262GAACA		insertion			alt_voc_name=(20J/501Y.V3;501Y.V3;Brazil variant;Manaus variant;B.1.1.28.1)	Madeline			
P.1	VOC	N	y	28512	C	G	P80R	nonsynonymous			alt_voc_name=(20J/501Y.V3;501Y.V3;Brazil variant;Manaus variant;B.1.1.28.1)	Madeline			
P.1	VOC	N	n	AGTAGGG28877-83TCTAAAC	AGTAGGG	TCTAAAC	RG203KR	nonsynonymous							
A.23.1	Recombinant	S	y				F157L	nonsynonymous				Anoosha			
A.23.1	Recombinant	S	y				V367F	nonsynonymous				Anoosha			
A.23.1	Recombinant	S	y				Q613H	nonsynonymous				Anoosha			
A.23.1	Recombinant	S	y				P681R	nonsynonymous				Anoosha			
B.1.525	Recombinant	orf1ab	y				L4715F	nonsynonymous			B.1.525 (Nigeria) - information available so far	Anoosha			
B.1.525	Recombinant	S	y				Q52R	nonsynonymous				Anoosha			
B.1.525	Recombinant	S	y				E484K	nonsynonymous				Anoosha			
B.1.525	Recombinant	S	y				Q677H	nonsynonymous				Anoosha			
B.1.525	Recombinant	S	y				F888L	nonsynonymous				Anoosha			
B.1.525	Recombinant	E	y				L21F	nonsynonymous				Anoosha			
B.1.525	Recombinant	E	y				I82T	nonsynonymous				Anoosha			
B.1.525	Recombinant		y		9 deletions		del:11288:9	deletion				Anoosha			
B.1.525	Recombinant		y		6 deletions		del:21765:6	deletion				Anoosha			
B.1.525	Recombinant		y		3 deletions		del:28278:3	deletion				Anoosha			
B.1.429	VOI	ORF1a					T265I					Anoosha			
B.1.429	VOI	ORF1a					I4205V					Anoosha			
B.1.429	VOI	ORF1b					P314L					Anoosha			
B.1.429	VOI	ORF1b					D1183Y					Anoosha			
B.1.429	VOI	S					S13I					Anoosha			
B.1.429	VOI	S					W152C					Anoosha			
B.1.429	VOI	S					L452R					Anoosha			
B.1.429	VOI	S					D614G					Anoosha			
B.1.429	VOI	ORF3a					Q57H					Anoosha			
B.1.429	VOI	N					T205I					Anoosha			
B.1.427	VOI	S					D614G					Anoosha			
B.1.427	VOI	ORF1a					T265I					Anoosha			
B.1.427	VOI	ORF1b					D1183Y					Anoosha			
B.1.427	VOI	N					T205I					Anoosha			
B.1.427	VOI	S					L452R					Anoosha			
B.1.427	VOI	ORF1a					S3158T					Anoosha			
B.1.427	VOI	ORF1b					P976L					Anoosha			
B.1.427	VOI	ORF3a					Q57H					Anoosha			
B.1.526	VOI	ORF1b					Q1011H					Anoosha			
B.1.526	VOI	S					D253G					Anoosha			
B.1.526	VOI	S					D614G					Anoosha			
B.1.526	VOI	ORF1b					P314L					Anoosha			
B.1.526	VOI	ORF1a					L3201P					Anoosha			
B.1.526	VOI	ORF1a					T265I					Anoosha			
B.1.526	VOI	ORF3a					Q57H					Anoosha			
B.1.526	VOI	S					T95I					Anoosha			
B.1.526	VOI	ORF3a					P42L					Anoosha			
B.1.526	VOI	ORF8					T11I					Anoosha			